High Falls Advisors’s GSK GSK Stock Holding History

High Falls Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-6,570	Closed	-$354K	–	89
2017 Q2	$354K	Buy	6,570 +308	+5%	+$16.4K	0.14%	58
2017 Q1	$330K	Buy	+6,262	New	+$318K	0.14%	66

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

High Falls Advisors's GSK Position: Q3 2017 in Review

High Falls Advisors sold out of GSK (GSK) in Q3 2017, closing a stake of 6,570 shares — an estimated $354K sold.

High Falls Advisors first reported a position in GSK in Q1 2017 and held it in 2 quarters. The position peaked at $354K in Q2 2017. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2017.

High Falls Advisors reported no remaining GSK position as of Q3 2017 after selling out during the quarter.
High Falls Advisors sold 6,570 GSK shares in Q3 2017, an estimated $354K.
High Falls Advisors first reported a position in GSK in Q1 2017 and held it in 2 quarters.
High Falls Advisors's GSK position peaked at $354K in Q2 2017.
742 funds tracked by Wall St. Rank held GSK as of Q3 2017.

Based on High Falls Advisors's 13F filing for Q3 2017, filed 15 Nov 2017.